Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.

Authors

null

Javier A. Cienfuegos

Department of General Surgery, Clinica Universidad de Navarra, Pamplona, Spain

Javier A. Cienfuegos , Fernando Rotellar , Jorge Baixauli , Carmen Beorlegui , Iosu Sola , Leire Arbea , Carlos Pastor , Jorge Arredondo , Jose Luis Hernandez-Lizoain

Organizations

Department of General Surgery, Clinica Universidad de Navarra, Pamplona, Spain, HPB Surgery, Clinica Universidad de Navarra, Pamplona, Spain, General Surgery, Clinica Universidad de Navarra, Pamplona, Spain, University Clinic of Navarre, University of Navarre, Pamplona, Spain, Laboratory of Pathology, Clinica Universidad de Navarra, Pamplona, Spain, Radiation Oncology, Clinica Universidad de Navarra, Pamplona, Spain, Fundación Jiménez Díaz, Madrid, Spain, Complejo Hospitalario de León, León, Spain

Research Funding

No funding sources reported

Background: The prognostic significance of perineural and/or lymphovascular invasion (PLVI) and its relationship with tumor regression grade (TRG) in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CRT) and surgery. Methods: A total of 324 patients with LARC treated with CRT were operated on between January 1992 and June 2007. Tumors were graded using a quantitative 5-grade TRG classification, and the presence of PLVI was studied histologically. Results: At a median follow-up of 79.0 months (range 3–250 months), a total of 80 patients (24.7%) relapsed. The observed 5- and 10-year overall survival (OS) was 83.2% and 74.9% respectively. The 5- and 10-year disease-free survival (DFS) was 75.1% and 71.4%, respectively. A significant correlation was found between the TRG and survival (log rank, p<0.001). The 10-year OS and DFS was 32.7% and 31.8% for grade 1; 63.8% and 58.6% for grade 2; 75.0% and 70.4% for grade 3; 90.4% and 88.4% for grade 3+, and 96.0% and 97.1% for grade 4. In patients with PLVI, the TRG had no impact on survival. When excluding patients with PLVI, TRG was an independent prognostic factor for OS and DFS. Conclusions: The presence of PLVI is a more powerful prognostic factor than TRG in LARC patients treated with neoadjuvant CRT followed by surgery. PLVI denotes an aggressive phenotype, suggesting that these patients may benefit from adjuvant systemic therapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 695)

DOI

10.1200/jco.2015.33.3_suppl.695

Abstract #

695

Poster Bd #

D37

Abstract Disclosures